A company with plans to revolutionise epilepsy monitoring has finally listed on the Australian stock exchange, culminating a journey that began when a medical student's father developed the neurological disorder.
Epiminder shares were trading at $1.34 on Monday afternoon, down 10.7 per cent from their IPO price of $1.50, giving the Cochlear-backed medical technology firm a market capitalisation of $290 million.
